MCL1/CDK9 screen published in eLife

Our CRISPR screening projects are starting to come out! Today work from postdoc Shaheen Kabir, in collaboration with oncologists at AstraZeneca, was published in eLife. Shaheen used a very creative FACS screen to find genes involved in the early apoptotic response to CDK9 and MCL1 inhibitors. Inhibition of CDK9 reduces transcript half-life and indirectly inhibits MCL1, whereas the other compound screen directly binds MCL1. Several cancers respond well to these new compounds, but others are already completely resistant. Shaheen went looking for genes involved in this resistance and found some very interesting shared hits. She focused her mechanistic work on the CUL5 ubiquitin ligase complex, which is a multi-component system used to degrade target proteins. Almost every component of the CUL5 complex was a hit in the screen, and Shaheen found that knockdown of CUL5 components affected the stability of pro-apoptotic proteins Bim and Noxa. CUL3 type ligases are already established cancer targets, and Shaheen’s work shows that CUL5 could also be targeted to synergize with front-line cancer therapeutics. Congratulations Shaheen!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

September 8, 2021

Congratulations to Mandy!

Congratulations to Mandy and team for winning the audience vote at the ETH 3Pi Pitch Competition, where ETH Pioneer Fellows pitched their projects to an audience...

September 1, 2021

Lab retreat in Zermatt

Our lab retreat for 2021 was held in Zermatt, in view of the Matterhorn. We spent the first day doing extemporaneous speed talks (3 minutes maximum!) and discussing...

June 17, 2021

Congratulations to Eric and John on the EMBO fellowships!

We are excited to share the news that Eric Aird and John Fielden were both awarded EMBO long-term fellowships, which support excellent postdoctoral researchers...

News Archive

Tweets